A new study shows that a 70-year-old malaria drug can block immune cells in the liver so nanoparticles can arrive at their intended tumor site, overcoming a significant hurdle of targeted drug delivery, according to a team of researchers led by Houston Methodist.
Many cancer patients do not respond to chemotherapies because the drugs never reach the cancer cells. Even in nanomedicine, which is one of the best new methods for delivering drugs to a tumor, only about one percent of a dose of nanoparticles will successfully arrive at the intended tumor site, while the rest are filtered out by the immune cells of the liver and spleen.
Using chloroquine, the researchers not only increased the circulation of nanoparticles in the body, but also reduced the body’s filtration of nanoparticles, as well as improved drug delivery to breast tumors. The study was recently published in Scientific Reports, a research journal from the Nature Publishing Group.
Led by Mauro Ferrari, Ph.D., president and CEO of the Houston Methodist Research Institute, and Joy Wolfram, Ph.D. (now at Mayo Clinic’s campus in Jacksonville, Florida), the research showed that chloroquine interfered with immune cells called macrophages, which are used by the body to identify microscopic foreign objects and destroy them.
In this study, mice models received injections of chloroquine, followed by an injection of nanoparticles. Chloroquine decreased the macrophages’ ability to clean up the nanoparticles. The findings are significant, because the nanoparticles not only remained in circulation, but also accumulated in mouse tumors, as well as in the lungs of healthy mice, suggesting that the approach also may enhance treatment for lung diseases.
Chloroquine was invented in the 1940s for the prevention and treatment of malaria. Since it mildly suppresses the immune system, the drug also is used in some autoimmune disorders, such as rheumatoid arthritis and lupus. Apart from this research, the drug is also being studied in other cancers, such as triple-negative breast cancer and pancreatic cancer.
Ferrari, considered one of the founders of nanomedicine and transport oncophysics (the physics of mass transport within a cancer lesion), says researchers and clinicians need to understand the limitations of transport mechanisms to identify effective immunotherapy treatments for patients.
Learn more: AGE-OLD MALARIA TREATMENT FOUND TO IMPROVE NANOPARTICLE DELIVERY TO TUMORS
The Latest on: Drug delivery
[google_news title=”” keyword=”drug delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Transdermal Drug Delivery Systems Market Strategies: How to Stay Competitive in 2024-2032on May 9, 2024 at 6:07 pm
Global Transdermal Drug Delivery Systems Market is valued approximately at USD 59.16 billion in 2022 and is anticipated to grow with a growth rate of more than 11.90% over the forecast period ...
- Ocular Drug Delivery Market Updates 2024 : Rise in…on May 9, 2024 at 3:30 am
According to a new report published by Allied Market Research, titled, “Ocular Drug Delivery Market,” The ocular drug delivery market size was valued at $67.7 billion in 2022, and is estimated to ...
- $375+ Billion Drug Delivery Devices Markets - Global Industry Size, Share, Trends, Opportunity, and Forecasts, 2019-2023 and 2024-2029Fon May 8, 2024 at 6:01 am
Global drug delivery devices are specialized instruments designed for administering drugs or therapeutic materials through specific routes. These medical treatments involve utiliz ...
- John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, Named Winner of RDD Conference’s Charles G. Thiel Awardon May 8, 2024 at 5:00 am
At the recent RDD Conference, John Patton, Ph.D., Head of Kindeva SAB, was announced as the winner of the Charles G. Thiel Award.
- Media Release: Sensirion product announcement: miniature liquid flow sensor platform for subcutaneous drug deliveryon May 8, 2024 at 1:08 am
Media Release: Sensirion product announcement: miniature liquid flow sensor platform for subcutaneous drug delivery 08.05.2024 / 08:08 CET/CEST Media Release 08.05.2024, Sensirion AG, 8712 Stäfa, ...
- Injectable drug delivery market poised for 8.6% CAGR growth until 2029on May 7, 2024 at 10:26 pm
The market’s revenue is set to reach $1139.4b within the forecast period. Revenue for the global injectable drug delivery market is set to grow by $1139.4b at a compound annual growth rate (CAGR) of 8 ...
- Advanced Dermatology Drug Delivery Devices Market Potential: Growth Areas and New Opportunities for 2032on May 7, 2024 at 9:59 pm
Report Ocean published the latest research report on the Advanced Dermatology Drug Delivery Devices market. In order to comprehend a market holistically, a variety of factors must be evaluated, ...
- NTU scientists develop revolutionary drug delivery system inspired by caterpillarson May 7, 2024 at 8:47 pm
SINGAPORE: A team of scientists from Nanyang Technological University (NTU) has created a novel drug delivery system that draws inspiration from the natural world. Using the unique self-assembling ...
- Sustained drug delivery: Advancing long-acting injectables (LAIs) with biodegradable microsphereson May 2, 2024 at 9:02 pm
Long-acting injectables (LAIs) are sustained drug delivery systems specifically designed so that medication is released into the body gradually over an extended period of time. Image Credit: Powder ...
- Drug device maker names operations chief ahead of St. Louis-area expansionon May 2, 2024 at 5:21 am
A manufacturer of drug-delivery devices has named a St. Louis-based operations chief to oversee its global operations as it completes a $100 million expansion of a local facility. A manufacturer of ...
via Google News and Bing News